CER TEK ENTERPRISES

Cer Tek Enterprises is a biotechnology company focused on innovative drug discovery and development, targeting mucosal pathogens with advanced genetic engineering techniques to enhance clinical outcomes and address unmet medical needs. Founded in 2017 in Los Angeles, US, Cer Tek Enterprises specializes in developing therapeutics for mucosal diseases. The company raised USD 0. 8 mn in Seed funding on January 11, 2018, achieving a current valuation of USD 0.

85 mn. The founder, Isaac Gesser, has a background in the biotechnology sector that informs the company's strategic direction. Cer Tek Bio Corp specializes in an innovative drug discovery platform that develops therapeutics specifically targeting mucosal pathogens and diseases lacking effective treatments. The core offerings include engineered microbial strains for therapeutic proteins and immune-modulating molecules, utilizing advanced genetic engineering techniques such as CRISPR.

The biomedical engineering team also produces diagnostic hardware, robotic assistive devices, and clinical tools aimed at improving interactions within healthcare settings, primarily serving providers and research institutions across North America, Europe, and select Asian markets. Cer Tek Bio Corp generates revenue through partnerships with healthcare providers and research entities, as well as potential collaborations with pharmaceutical companies for its therapeutic products. Revenue streams are driven by B2B agreements, long-term contracts, and sales of customizable microbial production systems and diagnostic tools, priced competitively to reflect their innovative nature and impact on patient care. Following the Seed funding of USD 0.

8 mn raised in January 2018, Cer Tek Enterprises plans to utilize these funds to develop new products that address unmet medical needs. The company is focusing on expanding its operations into new markets across Europe and Asia by 2025, enhancing its therapeutic solutions and delivery mechanisms. Upcoming product launches are aimed at improving treatment options for mucosal diseases.